News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
HIMSS event listings lack substance on healthcare modernization
Healthcare IT News page shows only conference promotions with no actual content on modernization challenges or solutions.
Florida clinic cuts documentation time 85% with AI scribe platform
First Rehabilitation reduced therapist note time from 40 minutes to 5 minutes per patient while growing revenue 37% year-over-year.
Viridian's thyroid eye drug shows promise after Phase 3 miss
New chronic disease data for elegrobart looks competitive with Amgen's Tepezza after earlier trial disappointed investors.
CellCentric raises $220M for oral multiple myeloma drug
Series D round funds Phase 2/3 trials of inobrodib, targeting p300/CBP proteins in combination with existing treatments.
Avalo skin drug succeeds in trial; BioNTech cuts plants
Avalo reported positive study results for hidradenitis suppurativa treatment while BioNTech announced facility closures and staff reductions.
Novo's Wegovy pill hits $354M in Q1, beats estimates by 95%
The oral GLP-1 drug generated 2 million prescriptions since January launch, prompting Novo to revise full-year guidance upward as it competes with Lilly.
Bayer buys Perfuse for $2.45B to expand eye drug portfolio
The deal centers on a mid-stage glaucoma therapy and marks Bayer's first pharma acquisition in years, potentially its largest since AskBio in 2020.
CellCentric raises $220M Series D for myeloma pill
22-year-old biotech secures funding to target patients who have exhausted all other treatment options.
GSK signs $1B siRNA deal with China's SiranBio
British pharma giant doubles down on cardiometabolic treatments through partnership with Suzhou-based startup in crowded obesity space.
Avalo raises $375M after Phase 2 trial win in skin disorder
Biotech secured mid-stage success for experimental drug targeting inflammatory skin conditions as part of broader comeback strategy.
ParcelBio raises $13M for mRNA delivery tech
Two ex-Orbital scientists claim breakthrough in mRNA delivery, launch startup with seed funding to address technical bottlenecks.
Madrigal's MASH drug Rezdiffra beats Q1 estimates by $10M
Rezdiffra posted $311 million in first quarter sales, exceeding analyst projections in a competitive liver disease market.